This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baltch, A. L.
Right arrow Articles by Bopp, L. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baltch, A. L.
Right arrow Articles by Bopp, L. H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 1998, p. 2564-2568, Vol. 42, No. 10
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Comparison of Inhibitory and Bactericidal Activities and Postantibiotic Effects of LY333328 and Ampicillin Used Singly and in Combination against Vancomycin-Resistant Enterococcus faecium

Aldona L. Baltch,* Raymond P. Smith, William J. Ritz, and Lawrence H. Bopp

Stratton Veterans Affairs Medical Center and Albany Medical College, Albany, New York 12208

Received 9 February 1998/Returned for modification 16 April 1998/Accepted 21 July 1998

One hundred ninety-five individual vancomycin-resistant Enterococcus faecium (VRE) isolates from five upstate New York hospitals were studied for antimicrobial susceptibilities to LY333328, quinupristin-dalfopristin, teicoplanin, ampicillin, and gentamicin. LY333328 was the most active antibiotic against VRE. The effect of media and methods on the antibacterial activity of LY333328, its synergy with ampicillin, and the postantibiotic effects (PAE) of LY333328 and ampicillin were evaluated. In microdilution tests, the MIC of LY333328 at which 90% of the isolates were inhibited (MIC90) was 2 µg/ml in Mueller-Hinton II (MH II) broth and 1 µg/ml in brain heart infusion (BHI) broth. In contrast, on MH II agar the MIC90 was 4 µg/ml and on BHI agar it was >16 µg/ml. Bactericidal activity was observed for most strains at concentrations from 8 to >= 133 times the MIC of the tube macrodilution in MH II broth. A bactericidal effect of LY333328 plus ampicillin was demonstrated in time-kill studies, but there was great strain-to-strain variability. By the MH II agar dilution method, bacteristatic synergy (defined as a fractional inhibitory concentration of <0.5) with LY333328 and ampicillin was demonstrated for 61% of the strains tested. Under similar conditions, there was synergy with LY333328 and quinupristin-dalfopristin or gentamicin for 27 and 15% of the strains tested, respectively. The PAE of LY333328 was prolonged (23.0 h at 10 times the MIC). However, 50% normal pooled human serum decreased the PAE to 12.2 h at 10 times the MIC. Test conditions and media had a considerable effect on VRE susceptibilities to LY333328. The prolonged PAE of LY333328, a potent new bactericidal glycopeptide, and its synergy with ampicillin in a large proportion of strains suggest that further evaluation of this drug in pharmacokinetic studies and experimental infections, including those with VRE, is warranted.

* Corresponding author. Mailing address: Infectious Disease Section, 111D, Stratton VA Medical Center, 113 Holland Ave., Albany, NY 12208. Phone: (518) 462-3311, ext. 3080. Fax: (518) 462-3350. E-mail: BALTCH.ALDONA{at}Albany.va.gov.

Antimicrobial Agents and Chemotherapy, October 1998, p. 2564-2568, Vol. 42, No. 10
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • McKay, G. A., Beaulieu, S., Arhin, F. F., Belley, A., Sarmiento, I., Parr, T. Jr, Moeck, G. (2009). Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother 63: 1191-1199 [Abstract] [Full Text]  
  • Belley, A., Neesham-Grenon, E., Arhin, F. F., McKay, G. A., Parr, T. R. Jr., Moeck, G. (2008). Assessment by Time-Kill Methodology of the Synergistic Effects of Oritavancin in Combination with Other Antimicrobial Agents against Staphylococcus aureus. Antimicrob. Agents Chemother. 52: 3820-3822 [Abstract] [Full Text]  
  • Attwood, R. J., LaPlante, K. L. (2007). Telavancin: A novel lipoglycopeptide antimicrobial agent. Am J Health Syst Pharm 64: 2335-2348 [Abstract] [Full Text]  
  • Van Bambeke, F., Carryn, S., Seral, C., Chanteux, H., Tyteca, D., Mingeot-Leclercq, M.-P., Tulkens, P. M. (2004). Cellular Pharmacokinetics and Pharmacodynamics of the Glycopeptide Antibiotic Oritavancin (LY333328) in a Model of J774 Mouse Macrophages. Antimicrob. Agents Chemother. 48: 2853-2860 [Abstract] [Full Text]  
  • Brown, J., Freeman, B. B III (2004). Combining Quinupristin/Dalfopristin with Other Agents for Resistant Infections. The Annals of Pharmacotherapy 38: 677-685 [Abstract] [Full Text]  
  • Cabellos, C., Fernandez, A., Maiques, J. M., Tubau, F., Ardanuy, C., Viladrich, P. F., Linares, J., Gudiol, F. (2003). Experimental Study of LY333328 (Oritavancin), Alone and in Combination, in Therapy of Cephalosporin-Resistant Pneumococcal Meningitis. Antimicrob. Agents Chemother. 47: 1907-1911 [Abstract] [Full Text]  
  • Boylan, C. J., Campanale, K., Iversen, P. W., Phillips, D. L., Zeckel, M. L., Parr, T. R. Jr. (2003). Pharmacodynamics of Oritavancin (LY333328) in a Neutropenic-Mouse Thigh Model of Staphylococcus aureus Infection. Antimicrob. Agents Chemother. 47: 1700-1706 [Abstract] [Full Text]  
  • Rupp, M. E., Fey, P. D., Longo, G. M. (2001). Effect of LY333328 against vancomycin-resistant Enterococcus faecium in a rat central venous catheter-associated infection model. J Antimicrob Chemother 47: 705-707 [Abstract] [Full Text]  
  • Coyle, E. A., Rybak, M. J. (2001). Activity of Oritavancin (LY333328), an Investigational Glycopeptide, Compared to That of Vancomycin against Multidrug-Resistant Streptococcus pneumoniae in an In Vitro Pharmacodynamic Model. Antimicrob. Agents Chemother. 45: 706-709 [Abstract] [Full Text]  
  • Kozawa, O., Uematsu, T., Matsuno, H., Niwa, M., Kohno, K.-I., Kawato, A., Takahashi, K., Nagashima, S., Kanamaru, M. (2001). Pharmacokinetics of a New Parenteral Oligosaccharide Antibiotic, SCH27899 (Ziracin), in Healthy Subjects. Antimicrob. Agents Chemother. 45: 917-921 [Abstract] [Full Text]  
  • Cetinkaya, Y., Falk, P., Mayhall, C. G. (2000). Vancomycin-Resistant Enterococci. Clin. Microbiol. Rev. 13: 686-707 [Abstract] [Full Text]  
  • Tanaka, T., Nakayama, K., Machida, K., Taniguchi, M. (2000). Long-chain alkyl ester of AMP acts as an antagonist of glucose-induced signal transduction that mediates activation of plasma membrane proton pump in Saccharomyces cerevisiae. Microbiology 146: 377-384 [Abstract] [Full Text]  
  • Schouten, M. A., Voss, A., Hoogkamp-Korstanje, J. A. A., The European VRE Study Group, (1999). Antimicrobial Susceptibility Patterns of Enterococci Causing Infections in Europe. Antimicrob. Agents Chemother. 43: 2542-2546 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»